Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.61B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Biocryst Pharmaceuticals Inc as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 294
- +22 vs. Q1 2025
- Shares held
- 197.2M
- +22.9M (+13.1%) vs. Q1 2025
- Total value
- $1.77B
- +$453.3M (+34.5%) vs. Q1 2025
- New holders
- 52
- 114 more added
- Sold out
- 30
- 84 more reduced
2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 319 | $2.61B |
| Q1 2026 | 303 | $2.37B |
| Q4 2025 | 273 | $1.66B |
| Q3 2025 | 286 | $1.47B |
| Q2 2025 | 294 | $1.77B |
| Q1 2025 | 274 | $1.32B |
| Q4 2024 | 258 | $1.26B |
| Q3 2024 | 257 | $1.32B |
| Q2 2024 | 242 | $1.08B |
| Q1 2024 | 238 | $915.0M |
| Q4 2023 | 236 | $1.06B |
| Q3 2023 | 233 | $1.24B |
| Q2 2023 | 236 | $1.23B |
| Q1 2023 | 242 | $1.42B |
| Q4 2022 | 230 | $1.80B |
| Q3 2022 | 234 | $1.87B |
| Q2 2022 | 221 | $1.61B |
| Q1 2022 | 233 | $2.07B |
| Q4 2021 | 206 | $1.63B |
| Q3 2021 | 197 | $1.48B |
| Q2 2021 | 195 | $1.65B |
| Q1 2021 | 191 | $1.06B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Biocryst Pharmaceuticals Inc; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −96,288−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −83,470−100.0% | Sold out |
| Teza Capital Management LLC | 0 | $0 | 0.00% | −35,579−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −32,464−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −16,269−100.0% | Sold out |
| Diversified Trust Co | 0 | $0 | 0.00% | −15,795−100.0% | Sold out |
| Freestone Grove Partners LP | 0 | $0 | 0.00% | −14,735−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −13,700−100.0% | Sold out |
| Merit Financial Group, LLC | 0 | $0 | 0.00% | −13,360−100.0% | Sold out |
| SIH Partners, LLLP | 0 | $0 | 0.00% | −12,639−100.0% | Sold out |
| Syon Capital LLC | 0 | $0 | 0.00% | −12,105−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −11,670−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −10,574−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −3,985−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −3,713−100.0% | Sold out |
| Semmax Financial Advisors Inc. | 0 | $0 | 0.00% | −1,849−100.0% | Sold out |
| Continuum Advisory, LLC | 0 | $0 | 0.00% | −1,668−100.0% | Sold out |
| Ameriflex Group, Inc. | 0 | $0 | 0.00% | −1,300−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −529−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −439−100.0% | Sold out |
| Mather Group, LLC. | 0 | $0 | 0.00% | −355−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Kodai Capital Management LP | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |